Qinghai Spring Medicinal Resources Technology Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Xuefeng Zhang

Algemeen directeur

CN¥625.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	9.5yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

CEO

Xuefeng Zhang (54 yo)

9.5yrs

Tenure

CN¥625,600

Compensatie

Mr. Xuefeng Zhang serves as Chairman & GM of Qinghai Spring Medicinal Resources Technology Co., Ltd. since May 15, 2015.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Xuefeng Zhang	Chairman & GM	9.5yrs	CN¥625.60k	geen gegevens
Xuemin Gao	Independent Director	4.4yrs	CN¥60.00k	geen gegevens
Jin Zhang	Supervisor	2.5yrs	geen gegevens	geen gegevens

4.4yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600381 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Qinghai Spring Medicinal Resources Technology Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 21, 2024

Recent updates

Third quarter 2024 earnings released: CN¥0.053 loss per share (vs CN¥0.034 loss in 3Q 2023)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Second quarter 2024 earnings released: CN¥0.056 loss per share (vs CN¥0.037 loss in 2Q 2023)

New major risk - Share price stability

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2024 Results on Aug 02, 2024

Qinghai Spring Medicinal Resources Technology Co., Ltd., Annual General Meeting, Jun 21, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: CN¥0.046 loss per share (vs CN¥0.049 loss in 1Q 2023)

Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) announces an Equity Buyback for CNY 50 million worth of its shares.

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q1, 2024 Results on Apr 24, 2024

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released: CN¥0.034 loss per share (vs CN¥0.045 loss in 3Q 2022)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: CN¥0.037 loss per share (vs CN¥0.043 loss in 2Q 2022)

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2023 Results on Aug 28, 2023

First quarter 2023 earnings released: CN¥0.049 loss per share (vs CN¥0.04 loss in 1Q 2022)

Third quarter 2022 earnings released: CN¥0.045 loss per share (vs CN¥0.017 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.043 loss per share (vs CN¥0.07 loss in 2Q 2021)

Full year 2021 earnings released: CN¥0.42 loss per share (vs CN¥0.54 loss in FY 2020)

Third quarter 2021 earnings released: CN¥0.017 loss per share (vs CN¥0.066 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.08 loss in 2Q 2020)

Full year 2020 earnings released: CN¥0.54 loss per share (vs CN¥0.01 profit in FY 2019)

New 90-day high: CN¥7.12

New 90-day high: CN¥6.86

New 90-day high: CN¥6.24

Hongta Hotland Asset Management Co., Ltd. completed the acquisition of 5.62% stake in Qinghai Spring Medicinal Resources Technology Co., Ltd. (SHSE:600381) from Tibet Rongen Technology Co., Ltd.

Third quarter earnings released

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report Q3, 2020 Results on Oct 22, 2020

First half earnings released

New 90-day high - CN¥6.00

Qinghai Spring Medicinal Resources Technology Co., Ltd. to Report First Half, 2020 Results on Aug 31, 2020

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd